Abstract Seventy-six homosexual or bisexual men underwent two cranial MRI studies at a mean interval of 13 months; 23 were HIV seronegative, 41 seropositive but asymptomatic (Center for Disease Control (CDC) groups II1III), and 12 had AIDS related complex (ARC)IAIDS (CDC group IV). Agreement between two neuroradiologists was rated as very good for assessment of enlargement of ventricles and good for widening of cerebral sulci and the presence of focal lesions. For assessment of serial studies, the agreement was moderate. The prevalence of cerebral atrophy and focal white matter lesions was no higher in the asymptomatic patients (CDC group II/III) than in appropriate seronegative controls. Some patients with ARC/AIDS showed evidence of developing cerebral atrophy during the study period when serial scans were compared. The imaging evidence supports the other data obtained from this cohort, which suggest that no significant CNS involvement occurs in HIV infection before the development of ARC/AIDS.
(CDC) groups II1III), and 12 had AIDS related complex (ARC)IAIDS (CDC group IV) . Agreement between two neuroradiologists was rated as very good for assessment of enlargement of ventricles and good for widening of cerebral sulci and the presence of focal lesions. For assessment of serial studies, the agreement was moderate. The prevalence of cerebral atrophy and focal white matter lesions was no higher in the asymptomatic patients (CDC group II/III) than in appropriate seronegative controls. Some patients with ARC/AIDS showed evidence of developing cerebral atrophy during the study period when serial scans were compared. The The neurological manifestations such as meningitis,' a cauda equina syndrome,2 myelitis,3 and encephalitis4 that may accompany HIV seroconversion suggest that, at least in some patients, the virus enters the nervous system early in the course of the disease. Furthermore, studies on CSF show cytochemical abnormalities in up to twothirds of asymptomatic patients in the Center for Disease Control (CDC) groups II/III; HIV can be cultured from CSF in one third of these. 5 HIV encephalopathy or the AIDS dementia complex has been estimated to occur in 6-5%-66% of patients with AIDS.67 This wide range reflects variables such as patient selection bias, criteria used for diagnosis, and the stage of disease. Clinically there is a decline in cognitive function often associated with motor and behavioural dysfunction. The diagnosis is one of exclusion of conditions such as depressive pseudodementia, metabolic derangement, opportunistic infections, and tumours. Although there are no pathognomonic clinical, neurophysiological, or CSF tests, imaging studies may help to support a diagnosis of HIV encephalopathy.
The commonest finding on CT is one of sulcal widening or ventricular dilatation, or both. MRI . may show evidence of diffuse white matter lesions on T-2 weighted images.8
The issue of subclinical neurological involvement in the asymptomatic patient infected with HIV is still contentious and has important medical, social, and political implications as almost 10 million people are thought to be infected with the virus worldwide. MRI is more sensitive than CT and has proved useful in the investigation of neurologically symptomatic patients with AIDS. 9 We argued that the detection of early subclinical encephalopathy might be possible with such investigative techniques in asymptomatic patients. If so, such imaging could be used to assess progression of disease and response to treatment, and also to help in elucidating the pathogenetic mechanisms involved in HIV infection.
In (1) cerebral atrophy-defined as ventricular dilatation and/or sulcal widening; (2) the presence of focal lesions classified as single, multiple or diffuse. The location and the presence of mass effect or associated oedema were also noted.
Incidental finding such as arachnoid cysts found in two subjects were not classified as abnormal. In cases of disagreement between the observers, the images were reviewed jointly and an attempt at a consensus decision was made. If no agreement was reached the study was excluded from further analysis.
At a separate session each radiologist reviewed both sets of images to assess whether any change had occurred. Specific note was made of any change in cerebral atrophy. Changes in the focal lesions were classified as: (1) lesions only on the second study; (2) increase, decrease, or no change in the number of lesions; (3) increase or decrease in the size of the lesions. Again, in cases of disagreement, an attempt at consensus was made.
STATISTICAL METHODS
The data were analysed with the Statistical Package for the Social Sciences (SPSSX).
Group analyses were carried out with the x2 test and the Kruskall-Wallis test was used to analyse the cerebral atrophy and alcohol data. The degree of interobserver agreement was calculated with the kappa statistic, which takes into account the probability of a chance agreement.'4 To interpret the K values as an indicator of the degree of agreement the levels used were: less than 0-20 poor, 0-21 to 0 40 fair, 0.41 to 0.60 moderate, 0-61 to 0-80 good, and 0 81 to 1 00 very good.
Results

CROSS SECTIONAL ANALYSIS: FIRST STUDY
The degree of agreement between the two radiologists was very good (K = 0 90) for enlargement of ventricles, and good for the presence of focal lesions (K = 0 76) and for widening of cerebral sulci (K = 067). After the consensus meeting, three studies (one seronegative and two asymptomatic patients) were excluded from analysis because no agreement could be reached. One further study was excluded because a birth injury was thought to account for a parenchymal abnormality. Table 3 Focal lesions Focal white matter lesions were present on 10 studies: 7/22 (32%) seronegative patients, 2/38 (5%) asymptomatic patients, and 1/12 (8%) with ARC/AIDS. Lesions were single in eight cases (six seronegative, one asymptomatic, and one ARC/AIDS). Multiple lesions were found on one asymptomatic subject and one who was seronegative. No correlation was found between the presence of focal lesions and age, a positive TPHA test, alcohol intake, or use of amyl nitrate, cannabis, or cigarettes. The patients infected with HIV had no significant association with concentrations of fl2 microglobulin.
Cerebral atrophy andfocal lesions Two seronegative and two asymptomatic subjects had cerebral atrophy and focal lesions in the first study. The lesions were multiple in one seronegative patient.
LONGITUDINAL ASSESSMENT OF CHANGE
Seventy-six repeated studies were analysed from 23 HIV seronegative, 35 asymptomatic, and 18 subjects with ARC/AIDS; the last group included six who had been asymptomatic on entering the study.
The degree of agreement between the radiologists was moderate for change in cerebral atrophy (K = 041) and change in focal lesions (K = 0 58); there was total agreement (K = 1-0) for a change in size of the focal lesions. After discussion, only one set of images from a seronegative patient was excluded from further analysis because no agreement could be reached.
Increase or development of cerebral atrophy An increase in cerebral atrophy was found in 1/22 (4%) of seronegative patients. Atrophy developed during the study in only 1/35(3%) asymptomatic patient but also in 7/18 (39%) patients with ARC/AIDS, of whom three had progressed from being asymptomatic to ARC/AIDS during the study period (fig 1) .
The patients who developed cerebral atrophy were not significantly older, and did not have a higher alcohol intake or a longer time interval between the two MRI studies than those who did not develop similar changes. 
Change in focal lesions
cells, the pathological hallmark of HIV encephalitis, and viral antigens such as p24 were not found, there is a suggestion that subtle neuropathological changes may indeed be occurring during the clinically asymptomatic stages of HIV infection. 19 Due to the subjectivity of radiological reporting, some workers have found poor agreement between those interpreting MRI studies particularly with respect to the presence of atrophy.20 With the K statistic, we found that the degree of agreement was good for assessment of the cerebral sulci and the presence of focal lesions. Agreement was excellent for enlargement of ventricles. When assessing for any change between serial studies, however, the agreement was only moderate. Altogether three sets of images were excluded from the cross sectional study and one from the longitudinal study because of lack of agreement between the two radiologists, which was not resolved at a consensus meeting.
This study may be criticised technically on two aspects. Firstly, using 7 mm thick slices with a 1 mm gap results in partial volume effects and it is possible to overlook lesions. Secondly, no formal method was used to ensure accurate alignment for serial studies. As the techniques used applied to all three subject groups, these drawbacks should not detract from the final group results obtained and the conclusions drawn.
In the cross sectional study, we found no significant difference in the prevalence of cerebral atrophy between seronegative controls, asymptomatic patients infected with HIV, and patients with ARC/AIDS. The presence of atrophy correlated with alcohol intake. In the patients infected with HIV, there was no correlation between atrophy and the degree of immunosuppression as indicated by the fl,2-microglobulin concentration.
Serial MRI studies over a period of 13 months showed the development of cerebral atrophy in some of the ARC/AIDS group, including a number who had progressed from being asymptomatic to We found that single focal white matter lesions occurred significantly more often in seronegative patients (7/22; 32%) than in the asymptomatic patients (2/38; 5%). Although no correlation was found between a positive TPHA and focal white matter lesions, this may be misleading: with increasing immunosuppression the TPHA may revert to negative.26 In the HIV infected patients (CDC groups II/III and IV) no significant association with f2 microglobulin concentrations was found. The presence of cerebral atrophy at the first study was not predictive for the development of focal lesions at the second. The MACS study reported a 24% (15/62) prevalence of focal white matter lesions in a group of homosexual men uninfected with HIV, which is similar to our finding of 32%20; however, 26% (33/128) of their asymptomatic HIV infected group, compared with our finding of 5%, also had evidence of these white matter lesions. As in our study, no significant changes occurred over a 12 month period.
There is a lack of data on brain MRI studies in healthy low HIV risk subjects within the age group of our cohort. One such study found an 11% prevalence of white matter lesions in the 30 to 39 age group.27 A higher rate of 22% with presumed incidental white matter lesions was found in patients aged 21- It is not clear whether these findings can be extrapolated to account for the foci seen in younger people. We conclude, therefore, that MRI in asymptomatic HIV seropositive patients shows no evidence of a subclinical encephalopathy. Furthermore, no deterioration occurs over a period of 13 months. This concurs with the other findings of this multidisciplinary study including neurological, neurophysiological, and neuropsychological assessment. Focal white matter lesions are not, therefore, necessarily evidence of parenchymal damage by HIV. The development of cerebral atrophy may be seen in some patients with ARC/AIDS, including some who have only recently become symptomatic. Issues to be considered include collecting more data on a young population at low risk for HIV infection, to answer the question as to whether homosexual men have a higher prevalence of MRI abnormalities irrespective of HIV infection and determining whether quantitative MRI will be more sensitive to subclinical encephalopathy in asymptomatic patients infected with HIV than the qualitative methods described-in this study.
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